Telomir Pharmaceuticals, Inc.

Preclinical aging/oncology biotech with no revenue, explicit going-concern doubt, and a pending related-party merger.

Strengths

• Strong liquidity (current/quick ratio ~5.1, ~62nd pct) and favorable IND-enabling GLP tox results
• Worldwide Telomir-1 IP consolidation via the TELI merger ahead of a planned 2026 IND

Risks

• Explicit going-concern doubt; no revenue, ROE -176%, ROA -142% (bottom quintile)
• Entirely preclinical with binary IND/clinical and financing risk; founder/insider control and conflicts with MIRALOGX

Notable findings

• Going concernRisks Related to Our Operations and Financial Condition We are an early development-stage company with no revenues and our financial condition raises substantial doubt as to our ability to continue
• Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
• Exec changeRecent 8-K item 5.02 8-K ↗
• Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
• Notable holderHeld by 2 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC (as of 2026-03-31)
• Pending mergerRisks Relating to Our Proposed Merger with TELI Pharmaceuticals, Inc
• New fund positionNotable fund(s) opened this quarter: GOLDMAN SACHS GROUP INC